SCHEMBL3255583

SCHEMBL3255583

COc1cc(OC)c(S(=O)(=O)N(CC(N)=O)c2ccc(Cl)cc2Cc2ccccc2Cl)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 3/20 0.47
PKM P14618 1/20 0.43
KEAP1 Q14145 2/20 0.41
NFE2L2 Q16236 2/20 0.41
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41
HPGD P15428 1/20 0.41
ALDH1A1 P00352 3/20 0.39
MCOLN3 Q8TDD5 2/20 0.39
POLB P06746 2/20 0.38
MAPK1 P28482 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
FDFT1 P37268 1/20 0.37
GAA P10253 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3266443 0.94 PTGER1 (0.43) PTGER1PKMKEAP1NFE2L2HCRTR1
SCHEMBL3251134 0.91 PTGER1 (0.47) PTGER1PKMKEAP1NFE2L2HCRTR1
SCHEMBL3253378 0.90 LMNA (0.47) PTGER1PKMKEAP1NFE2L2HPGD
SCHEMBL14107544 0.90 PTGER1 (0.50) PTGER1PKMHPGDALDH1A1MCOLN3
SCHEMBL3247753 0.89 PKM (0.57) PTGER1PKMKEAP1NFE2L2HCRTR1
SCHEMBL3256139 0.86 PTGER1 (0.44) PTGER1KEAP1NFE2L2HCRTR2ALDH1A1
SCHEMBL3244429 0.84 PTGER1 (0.42) PTGER1KEAP1NFE2L2HCRTR2ALDH1A1
SCHEMBL3247610 0.84 KEAP1 (0.52) PKMKEAP1NFE2L2HCRTR1HCRTR2
SCHEMBL3253720 0.84 KEAP1 (0.62) KEAP1NFE2L2
SCHEMBL3250637 0.83 FDFT1 (0.39) PTGER1KEAP1NFE2L2HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 PTGER1 4534/4885PKM 2524/4885KEAP1 3317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.